Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etinoline is a beta adrenoagonist with a predominant effect on beta2-adrenergic receptors. It is utilized for the prevention and relief of bronchospasm in various forms of bronchial asthma, reversible airway obstruction in chronic bronchitis and emphysema, and bronchial obstruction in children. Additionally, it is indicated for threatening preterm labor with uterine contractions and as a preventive measure during surgery on the pregnant uterus. Its pharmacological action involves preventing and reducing bronchospasm, decreasing airway resistance, increasing vital capacity, and inhibiting the release of histamine and slow-reacting substances from mast cells. It exhibits a less pronounced positive chrono- and inotropic effect on the myocardium and promotes the widening of coronary arteries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Etinoline.